Sangamo BioSciences gives genome modification patent update

The U.S. Patent Office issues a notice of allowance for a claim covering "core architectural aspects of engineered Transcription Activator-Like Effectors."

Sangamo BioSciences (SGMO) says it expects the architectures "to be broadly adopted and become the industry standard."

The technology can be used to edit gene sequences when used with the company's "proprietary engineered FokI nucleases, or DNA cutting domains." (PR)

From other sites
Comments (1)
  • tomogren
    , contributor
    Comments (3) | Send Message
    Wow! Can you even imagine how big this will be?
    14 Aug 2013, 02:40 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs